Skip to main content
v2026.11,986 entries · CC-BY 4.0

21 CFR Part 212: PET Drug cGMP Requirements by Subpart

21 CFR Part 212 is FDA’s cGMP rule for PET drugs: what each subpart requires and when Parts 210/211 or USP 823 apply instead.

Written and maintained by CASRAI Editorial Board

Published

On this page

21 CFR Part 212 is the FDA regulation that sets current good manufacturing practice (cGMP) for positron emission tomography (PET) drugs. It covers production, quality assurance, holding and distribution of PET drugs, and it replaces Parts 210 and 211 for those drugs only: a human drug that does not meet the Part 212 definition of a PET drug must follow Parts 210 and 211 instead. The rule has twelve subparts, A to L, that run from personnel and quality assurance through batch release, distribution, complaints and records.

What 21 CFR Part 212 is and who it covers

Part 212 is titled “Current Good Manufacturing Practice for Positron Emission Tomography Drugs”. Its authority citations are 21 U.S.C. 321, 351, 352, 355, 371 and 374, and section 121 of Public Law 105-115, the Food and Drug Administration Modernization Act of 1997. FDA’s QandA guidance explains the background: section 121 directed FDA to establish approval procedures and cGMPs for PET drugs, and FDA published the Part 212 regulations in the Federal Register on 10 December 2009 (74 FR 65431).

Section 212.2 states what the rule is for. cGMP for PET drugs is “the minimum requirements for the methods to be used in, and the facilities and controls used for, the production, quality assurance, holding, or distribution of PET drugs intended for human use”, and it is meant to ensure that each PET drug meets the requirements of the Act as to safety and has the identity, strength, quality and purity it is supposed to have.

What counts as a PET drug

Section 212.1 defines a PET drug as a radioactive drug that exhibits spontaneous disintegration of unstable nuclei by the emission of positrons and is used for providing dual photon positron emission tomographic diagnostic images. The definition is wider than the finished injection: it also includes any nonradioactive reagent, reagent kit, ingredient, nuclide generator, accelerator, target material, electronic synthesizer, or other apparatus or computer program to be used in the preparation of a PET drug. A PET drug product is the finished dosage form.

That scope matters to research administrators because the rule reaches the equipment and software used to prepare the drug, not only the vial that leaves the building. A cyclotron facility, a radiochemistry core or a hospital radiopharmacy that prepares PET drugs for human use is a PET drug production facility under the definitions. The QandA guidance also separates two kinds of work in a single area: dispensing patient-specific doses by prescription is the practice of pharmacy, and the guidance says production and dispensing may share a work area as long as the layout and workflow prevent contamination and mix-ups.

Words the rule defines for production work

Several defined terms recur in every subpart. “Production” means manufacturing, compounding, processing, packaging, labeling, reprocessing, repacking, relabeling and testing. A “batch” is a specific quantity of PET drug intended to have uniform character and quality, produced according to a single production order during the same cycle of production, and a “sub-batch” is a quantity produced during one succession of multiple irradiations using a given synthesis or purification operation. “Final release” is the authoritative decision by a responsible person in a PET production facility to permit the use of a batch in humans, while “material release” is the equivalent decision for a component, container and closure, in-process material, packaging material or labeling. A “receiving facility” is any hospital, institution, nuclear pharmacy, imaging facility or other entity that accepts a PET drug product that has been given final release. Teams that already track these ideas for other products will find the same vocabulary in the cGMP facility term.

Which cGMP rule applies: Part 212, Parts 210 and 211, or USP chapter 823

Section 212.5 decides which cGMP rule governs a product, and it is the quickest way to avoid applying the wrong one. Part 212 applies only to PET drugs. Any human drug that does not meet the PET drug definition must be manufactured under Parts 210 and 211. For general finished-pharmaceutical cGMP, the CASRAI subpart map for 21 CFR 210 and 211 covers the other rule set, and the broader overview at current good manufacturing practice places both in context.

Section 212.5(b) adds a second route for two research-oriented situations. For investigational PET drugs produced under an investigational new drug application (IND) under Part 312, and for PET drugs produced with the approval of a Radioactive Drug Research Committee (RDRC) under Part 361, the statutory requirement to follow cGMP is met by complying with Part 212 or by producing the drug in accordance with USP chapter 823, “Radiopharmaceuticals for Positron Emission Tomography – Compounding” (1 May 2009, USP 32/NF 27), which the regulation incorporates by reference. The table below sets out the three routes as the regulation states them.

Situation cGMP that applies Source
Drug meets the Part 212 definition of a PET drug (commercial or clinical production) Part 212 21 CFR 212.5(a)
Human drug that is not a PET drug Parts 210 and 211 21 CFR 212.5(a)
Investigational PET drug under an IND (Part 312) Part 212 or USP chapter 823 21 CFR 212.5(b)
PET drug made with Radioactive Drug Research Committee approval (Part 361) Part 212 or USP chapter 823 21 CFR 212.5(b)

The alternative to Part 212 is stated only for those two cases. A producer working outside IND and RDRC arrangements has no USP 823 option in 212.5. FDA’s Q&A guidance describes the later regulatory background: Congress required that a new drug application (NDA) or abbreviated new drug application (ANDA) be submitted within two years of publication for any PET drug marketed for clinical use, and the guidance states that all PET producers had to be operating under an approved NDA or ANDA, or an effective IND, by 12 December 2015. Part 212 is therefore the cGMP layer that sits under those applications.

What each subpart requires

The twelve subparts follow the life of a batch. The data table below the Sources list maps every subpart to its section numbers, topic and the principal written requirement. The paragraphs here add the detail that table cannot carry.

Personnel, resources and quality assurance (subparts B and C)

Section 212.10 is short: you must have a sufficient number of personnel with the necessary education, background, training and experience, and adequate resources, including facilities and equipment, for them to perform their functions. Section 212.20 then lists what quality assurance must do. It must oversee production operations, examine and approve or reject components, containers, closures, in-process materials, packaging materials, labeling and finished dosage forms, and approve or reject any initial or changed specification, method, process or procedure before implementation. The producer must demonstrate that a change does not adversely affect identity, strength, quality or purity. Quality assurance must also review production records for errors, decide whether an investigation is needed when a batch or component fails a specification, and establish and follow written quality assurance procedures.

Facilities and equipment (subpart D)

Section 212.30 asks for facilities that ensure orderly handling of materials and equipment and prevent mix-ups and contamination by substances, personnel or environmental conditions. Equipment that could affect identity, strength, quality or purity, or give invalid test results if improperly maintained, must be clean, suitable, properly installed, maintained and capable of repeatedly producing valid results, and the activities must be documented. Product-contact surfaces must not be reactive, additive or absorptive so as to alter product quality. The QandA guidance adds that the rule sets no specific ceiling or floor material, although seamless ceilings and floors are recommended for a new facility so that they can be readily cleaned.

Components, containers and closures (subpart E)

Section 212.40 requires written procedures for receipt, login, identification, storage, handling, testing and acceptance or rejection, and written specifications for identity, quality and purity. Each incoming lot is uniquely identified and tested or examined, designated quarantined, accepted or rejected, and may not be used before material release. A reliable supplier must be the source. The identity-testing rule has two branches. If finished-product testing already confirms that the correct components were used, a supplier certificate of analysis is enough for incoming components and no specific identity test is required. If it does not, identity testing is required on each lot of a component that yields an active ingredient and on each inactive ingredient. FDA’s Q&A guidance illustrates the first branch with a fluorine-18 product whose radiochemical identity is confirmed on the finished product. A record is kept for each shipment, including supplier name and lot number, date of receipt, test results, disposition of rejected material and expiration date.

Production and process controls (subpart F)

Section 212.50 is the longest operational section. It requires written control procedures showing that key process parameters are controlled and deviations justified, master production and control records, and a unique batch production and control record each time a batch is made. The master record must state the name and strength of the drug, components, major equipment, component weights or measures, an action limit on radiochemical yield, production and testing instructions and a description of containers, closures and labels. The batch record carries a unique batch identifier, major production steps, dates and times of critical steps, equipment used, test results, labeling, initials or signatures for each significant step and the results of any investigations. Production areas and equipment are checked for cleanliness and suitability immediately before use, and a record of the check is kept. Process verification is not required when every batch undergoes full finished-product testing; otherwise the producer must demonstrate that the process is reproducible and document the verification. A paper or electronic batch record both satisfy the content list; the electronic route is covered under electronic batch record (eBR).

Laboratory controls and stability (subpart G)

Section 212.60 applies to each laboratory that tests components, in-process materials or finished PET drugs. It requires written test procedures, sampling and testing procedures aimed at established standards, analytical methods that are suitable, sufficiently sensitive, specific, accurate and reproducible, controlled reagents with solutions labeled with identity and expiration date, equipment that is calibrated, inspected, checked and maintained under written procedures, and complete test records. Those test records include sample identification, method description, calculations, all data including graphs, charts and spectra, results compared with acceptance criteria, and the initials or signature of the analyst with the test date. Section 212.61 requires a written stability testing program whose results set storage conditions and expiration dates and times. Where laboratory records are electronic, the FDA position on record reliability is discussed in FDA data integrity guidance for cGMP.

Finished-product controls and release (subpart H)

Section 212.70 requires specifications for each product covering identity, strength, quality, purity and, if appropriate, sterility and pyrogens. Before final release, a laboratory determination must show that each batch (or each sub-batch) conforms to specifications, except for sterility; the data are reviewed; and a designated qualified individual authorizes final release by dated signature. Sterility testing need not be completed before release, but it must be started within 30 hours after completion of production, with an allowance for weekends and holidays if the sample is shown not to be adversely affected. Samples must come from individual batches and not be pooled. A sterility failure triggers documented notification of all receiving facilities, with a second notification when the investigation is complete.

Section 212.71 requires rejection of a nonconforming batch, procedures to identify and segregate it, a documented investigation, correction of identified problems and, where appropriate, reprocessing under the procedures in the product’s approved application, with the product conforming to specifications except for sterility before final release.

Packaging, distribution, complaints and records (subparts I to L)

Section 212.80 requires labels that remain legible and affixed through processing, storage, handling, distribution and use, and states that all label information must also be contained in each batch production record. Section 212.90 requires written distribution procedures and records of the receiving facility, product and quantity, lot or batch number, and date and time shipped. Section 212.100 requires written complaint procedures covering quality, purity and possible adverse reactions, with review by a designated person of any complaint involving possible specification failure. Section 212.110 sets record availability at the production facility or another location reasonably accessible to responsible officials and FDA inspectors, requires records to be legible, stored to prevent deterioration or loss and readily available for review and copying, and requires retention for at least 1 year from the date of final release, including conditional final release.

Conditional final release: the one exception to complete testing

Section 212.70(f) lets a producer approve conditional final release when a required finished-product test cannot be completed because of a malfunction of analytical equipment. Six conditions apply together: data showing that preceding consecutive batches made with the same methods indicate the batch will likely meet specifications; all other acceptance criteria are met; a reserve sample is retained; the malfunction is promptly corrected and the omitted test is completed on the reserve sample; an out-of-specification result on the reserve sample is notified to the receiving facility immediately; and every action is documented. Conditional release is barred altogether if the malfunction prevents a radiochemical identity or purity test or the determination of specific activity, and no further batch may be released until the problem is corrected and the omitted test is completed. FDA’s Q&A guidance repeats the last point, noting that a reserve sample is needed to complete the finished-product testing.

Compliance steps in the order a batch moves

The regulation does not number a compliance procedure, so the sequence below is an editorial ordering of the sections above, not an FDA checklist. It is useful for building a self-inspection or internal audit plan for a PET production facility.

  1. Define the product and the rule. Confirm under 212.1 and 212.5 that the drug is a PET drug, and identify whether the work runs under an NDA or ANDA, an IND or an RDRC arrangement.
  2. Set up quality assurance and resources. Document personnel qualifications (212.10) and the written quality assurance procedures and approval authority (212.20).
  3. Qualify facilities and equipment. Write the equipment procedures and keep the records of cleaning, installation and maintenance (212.30).
  4. Control incoming materials. Write specifications and receipt procedures, quarantine and release each lot, and keep a record per shipment (212.40).
  5. Write master records, then run batches against them. Create a unique batch record each time, with area and equipment checks before use (212.50).
  6. Test, then release. Apply the specifications, review the data and obtain the dated signature of the designated qualified individual (212.60, 212.61, 212.70).
  7. Label, ship and listen. Control labeling, keep distribution records and handle complaints under written procedures (212.80, 212.90, 212.100).
  8. Retain records. Keep every record referenced in the part for at least 1 year from final release (212.110).

Typical phases of a batch

Read together, the sections describe five phases, each ending in a documented decision. Incoming materials end in a material release. Production ends in a completed batch record. Laboratory testing ends in a comparison of results with acceptance criteria. Release ends in a dated signature, or in rejection and investigation under 212.71. Distribution ends in a record of what went to which receiving facility. The one deliberate overlap is sterility: because the test may start up to 30 hours after production and need not finish before release, the release decision and the sterility result are separated in time, and the notification duty in 212.70(e) is what closes the gap if the result fails.

Common misreadings of Part 212

  • Applying Parts 210 and 211 to a PET drug. Section 212.5(a) says Part 212 applies to PET drugs; Parts 210 and 211 are for human drugs that are not PET drugs.
  • Assuming USP 823 is a general alternative. Section 212.5(b) names USP chapter 823 as an alternative only for IND and RDRC production.
  • Treating conditional release as routine. It is limited to analytical equipment malfunction, requires six conditions and cannot be used when the malfunction blocks radiochemical identity or purity or specific activity testing.
  • Pooling sterility samples. Section 212.70(e) requires tested samples to be from individual batches and not pooled.
  • Running specific identity tests on every component in all cases. Section 212.40(c)(1) allows a certificate of analysis for incoming components when finished-product testing confirms the correct components were used.
  • Counting retention from production. The one-year minimum in 212.110(c) runs from the date of final release, including conditional final release.
  • Leaving label text out of the batch record. Section 212.80(c) requires all information stated on each label to be contained in each batch production record.
  • Dispensing patient doses inside the hot cell. FDA’s QandA guidance says dispensing the pharmacy dose should not be done inside the hot cell and should comply with state pharmacy regulation and USP chapter 797.

Where Part 212 differs from clinical-trial good practice

Part 212 governs how a drug is made and released; it does not govern how a trial is run. Research offices that support PET imaging studies usually meet both: the producer follows Part 212 (or USP 823 in the IND and RDRC cases), and the study follows good clinical practice. The comparison GCP vs GMP explains how the two frameworks divide responsibility.

Document What it covers How it relates to Part 212
21 CFR Parts 210 and 211 cGMP for human drugs generally Apply to a human drug that is not a PET drug (212.5(a))
21 CFR Part 312 Investigational new drug applications IND production of a PET drug may follow Part 212 or USP 823 (212.5(b))
21 CFR Part 361 Radioactive Drug Research Committee RDRC-approved production may follow Part 212 or USP 823 (212.5(b))
USP chapter 823 Radiopharmaceuticals for PET – Compounding Incorporated by reference as the alternative in 212.5(b)
FDA guidance: FDA Oversight of PET Drug Products, Questions and Answers (December 2012) Application, chemistry and controls, cGMP, inspections, registration and user fees Nonbinding FDA reading of Part 212 requirements

FDA’s guidance documents describe the agency’s current thinking and, unless regulatory or statutory requirements are cited, are recommendations rather than enforceable responsibilities. The text of Part 212 itself is the binding source.

Sources

Data: 21 CFR Part 212 subpart map: sections, topic and principal requirement

Compiled from the text of 21 CFR Part 212 as published in the eCFR (current to 2026-11-13): one row per subpart A to L, giving the section numbers, the topic and the principal written or record requirement stated in those sections.

Period covered: 2026-11-13. Coverage: United States.

21 CFR Part 212 subpart map: sections, topic and principal requirement
SubpartSectionsTopicPrincipal requirement
A212.1-212.5General provisionsDefinitions of PET drug and related terms; scope limited to PET drugs; IND and RDRC alternative via USP 823
B212.10Personnel and resourcesSufficient personnel with education, background, training and experience; adequate facilities and equipment
C212.20Quality assuranceOversee production; approve or reject materials, specifications and changes; review records; written QA procedures
D212.30Facilities and equipmentPrevent mix-ups and contamination; equipment clean, maintained and documented; non-reactive contact surfaces
E212.40Components, containers and closuresWritten receipt and acceptance procedures and specifications; quarantine, accept or reject each lot; record per shipment
F212.50Production and process controlsMaster and batch production and control records; area and equipment checks; process verification where not fully tested
G212.60-212.61Laboratory controls and stabilityWritten test procedures and test records; calibrated equipment; written stability program setting storage and expiry
H212.70-212.71Finished product controls and acceptanceSpecifications; dated final release signature; sterility test started within 30 hours; reject and investigate nonconforming batch
I212.80Packaging and labelingLabels legible and affixed; all label information also in the batch production record
J212.90DistributionWritten distribution procedures; records of receiving facility, product, quantity, batch number, date and time shipped
K212.100Complaint handlingWritten complaint procedures; designated reviewer; investigation of possible specification failure
L212.110RecordsRecords accessible and legible; retained at least 1 year from final release including conditional final release

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about 21 CFR Part 212: PET Drug cGMP Requirements by Subpart

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →